MLYS Mineralys Therapeutics, Inc.
FY2025 10-K
Mineralys Therapeutics, Inc. (MLYS) filed its fiscal year 2025 10-K annual report with the SEC on Mar 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Business section lacks substantive description of core operations or products
- • Reliance on 2026 Proxy Statement for key corporate governance and executive compensation details
Management Discussion & Analysis
- • No revenue; net loss $154.7M in 2025 vs $177.8M in 2024, improvement of $23.1M
- • R&D expenses $132.0M in 2025 vs $168.6M in 2024, a 21.7% decrease; G&A expenses $38.6M vs $23.8M, a 62.0% increase
Risk Factors
- • Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
- • Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations
Get deeper insights on Mineralys Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.